TMCnet News
Bharat Book Bureau: PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis(M2 PressWIRE Via Acquire Media NewsEdge) Summary "PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis". Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available. The US influenza vaccine market is valued at approximately $1.05 billion in 2012. The projected drivers for market growth include increased patient awareness on the importance of being vaccinated against influenza, the introduction of vaccines with a quadrivalent formulation, a growing elderly population, and introduction of vaccines with improved efficacy in elderly patients. Sanofi is the current market leader. It was among the first influenza vaccines available in the US, and it has produced a diverse portfolio of influenza vaccines under Sanofi's Fluzone brand. This brand includes trivalent vaccines with novel routes of administration (Fluzone ID) and vaccines with enhanced immunogenicity in elderly recipients (Fluzone High-Dose). For more info: https://www.bharatbook.com/healthcare-market-research-reports-362991/influenza-vaccines-united-states--1.html Contact us at : Bharat Book Bureau Tel: +91 22 27810772 / 27810773 Toll Free No for USA/Canada : 1-866-279-8368 Email: [email protected] Website: www.bharatbook.com Follow us on twitter: https://twitter.com/researchbook Follow us on linked in : http://www.linkedin.com/company/bharat-book-bureau Our Blog : http://blog.bharatbook.com/ . (c) 2014 M2 COMMUNICATIONS |